文献速递结核与非结核分枝杆菌

利用数字NanoString nCounter平台建立并验证简约结核基因特征

Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.
PubMed 文献 · Clin Infect Dis · 2022-01-01

研究评估NanoString nCounter平台验证结核基因特征的能力,在印度南部结核患者与潜伏结核感染者的全血RNA中检测12个结核特征和6个管家基因,机器学习得出6基因集NANO6,并在10个已发表数据集中显示对活动性结核有高度诊断价值。

要点

  • NS-TB107包含12个结核特征和6个管家基因,对结核与潜伏感染有统计学显著区分力。
  • 机器学习得出NanoString 6基因集NANO6,在10个已发表数据集上对活动性结核高度诊断。
  • NanoString nCounter系统可作为验证结核生物标志物的稳健平台。

核心结论

  • NanoString nCounter系统为验证现有结核生物标志物和得出诊断性能增强的简约基因特征提供了稳健平台。

研究设计与样本

  • 研究使用NanoString平台在印度南部结核患者和潜伏结核感染者的全血RNA中对已有结核基因特征进行性能评估。
  • 开发了包含12个结核特征和6个管家基因共107个基因的NanoString代码集NS-TB107。
  • 使用TBSignatureProfiler工具对每个特征评分,并用机器学习算法集成得出简约生物标志物。

主要发现

  • NS-TB107中的基因特征对区分结核与潜伏结核感染具有统计学显著的判别力。
  • 数据分析得出NanoString 6基因集NANO6,在10个已发表数据集上对活动性结核高度诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blood-based biomarkers for diagnosing active tuberculosis (TB), monitoring treatment response, and predicting risk of progression to TB disease have been reported. However, validation of the biomarkers across multiple independent cohorts is scarce. A robust platform to validate TB biomarkers in different populations with clinical end points is essential to the development of a point-of-care clinical test. NanoString nCounter technology is an amplification-free digital detection platform that directly measures mRNA transcripts with high specificity. Here, we determined whether NanoString could serve as a platform for extensive validation of candidate TB biomarkers. METHODS: The NanoString platform was used for performance evaluation of existing TB gene signatures in a cohort in which signatures were previously evaluated on an RNA-seq dataset. A NanoString codeset that probes 107 genes comprising 12 TB signatures and 6 housekeeping genes (NS-TB107) was developed and applied to total RNA derived from whole blood samples of TB patients and individuals with latent TB infection (LTBI) from South India. The TBSignatureProfiler tool was used to score samples for each signature. An ensemble of machine learning algorithms was used to derive a parsimonious biomarker. RESULTS: Gene signatures present in NS-TB107 had statistically significant discriminative power for segregating TB from LTBI. Further analysis of the data yielded a NanoString 6-gene set (NANO6) that when tested on 10 published datasets was highly diagnostic for active TB. CONCLUSIONS: The NanoString nCounter system provides a robust platform for validating existing TB biomarkers and deriving a parsimonious gene signature with enhanced diagnostic performance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kaipilyawar V, Zhao Y, Wang X, et al. Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform. Clin Infect Dis. 2022. PMID: 35015839. doi:10.1093/cid/ciac010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。